Posted by Michael Wonder on 25 Nov 2015
Pfizer receives European approval to expand use of Xalkori (crizotinib) to first-line treatment of adults with ALK positive advanced non-small cell lung cancer
25 November 2015 - Pfizer Inc. today announced that the European Commission has approved a label update to expand use of Xalkori (crizotinib) to first-line treatment of adults with anaplastic lymphoma kinase positive advanced non-small cell lung cancer.
For more details, go to: http://www.businesswire.com/news/home/20151124006345/en/Pfizer-Receives-European-Approval-Expand-XALKORI®-crizotinib
